Constellation raises $15M in Series B extension financing

April 10, 2017

Time: Monday June 6, 8:00 AM to 12:00 PM

Location: McCormick Place Hall A

Dr. Ma and colleagues from Roswell Park Cancer Institute and University of Colorado School of Medicine presented final results of a phase I study of the combination of rigosertib and gemcitabine in 36 patients with advanced pancreatic cancer and other solid tumors. Only toxicities related to gemcitabine were observed and preliminary antitumor activity was measured in several patients, suggesting that rigosertib and gemcitabine is a well-tolerated combination with a promising basis for phase II evaluation in advanced metastatic pancreatic cancer patients.

Abstract# e13584

"Final results of a phase 1 dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors"

Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S.

Category: Developmental Therapeutics - Experimental Therapeutics

Session Title: New Targets, New Technologies

(Publication only, also published at ASCO on-line)

Dr. Ohnuma and colleagues from Mount Sinai School of Medicine, Montefiore Medical Center and Onconova Therapeutics will publish the final results of a dose-escalation study of rigosertib in combination with oxaliplatin in patients with advanced solid tumors. No dose limiting toxicity was seen in rigosertib treated patients and confirmed partial responses and stable disease were observed in several patients, leading to the conclusion that this combination was well-tolerated and resulted in objective tumor responses in advanced ovarian, breast, colon and renal cancer patients.

SOURCE Onconova Therapeutics, Inc.